Teneliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40. As of 2009[update], it has not entered clinical trials.[2]
References
- ^ International Nonproprietary Names For Pharmaceutical Substances
- ^ Iqbal S. Grewal, ed. (January 15, 2009). Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology). Springer. p. 22. ISBN 0-387-89519-1.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |